Evidence map›Paper›PMID 29732038›Full record

ArticleCaspian journal of internal medicine2018

Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier.

Zohreh Azarkar, Azadeh Ebrahimzadeh, Gholamreza Sharifzadeh, Masood Ziaee, Mohammad Fereidouni, Fatemeh Taheri

Open access · greenAbstract read
In one paragraph

Article in Caspian journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zohreh AzarkarInfectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Azadeh EbrahimzadehInfectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Gholamreza SharifzadehInfectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Masood ZiaeeInfectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Mohammad FereidouniAsthma, Allergy and Immunology Research Center, Medical Sciences of University, Birjand, Iran.
Fatemeh TaheriAsthma, Allergy and Immunology Research Center, Medical Sciences of University, Birjand, Iran.
Birjand University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Iran since 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim of this study was to evaluate the long - term persistence of immunity.

methodsThis cross-sectional analytical study was conducted on children and adolescents aged between 6-18 years in Birjand, who received a three - dose hepatitis B vaccination in accordance with the national immunization program. No students were infected with hepatitis B. Antibody titer higher than10 IU/L was considered positive.

resultsA total of 530 patients (307 boys and 223 girls) were recruited for the study of which 44% had positive antibody titer (≥10 IU / L). The geometric concentration mean (GMCs) of antibody in subjects was 64.9±34.2, HBS antibody titer was positive in 40.4% of the boys and 59.6% of the girls. A significant difference in antibody titers was observed in terms of gender and according to the time elapsed since the last vaccination. Antibody titer in children older than 13 years had passed since their last vaccination and was significantly less than those children younger than thirteen years old had passed since their vaccination logistic regression analysis showed that the only predictive factor of anti-HBS low titer (<10 IU/L) is elapsed time of vaccination.

conclusionsBased on results of this study, hepatitis B vaccine has created a good level of protection in 44% of the adolescents after 17 years.

Indexed as

Hepatitis BImmunityVaccination

Identifiers

PMID29732038
PMCPMC5912228
OpenAlexW2792187362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.